RT Journal Article
SR Electronic
T1 Multi-Sequence Average Templates for Aging and Neurodegenerative Disease Populations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.28.21259503
DO 10.1101/2021.06.28.21259503
A1 Mahsa Dadar
A1 Richard Camicioli
A1 Simon Duchesne
A1 For the CCNA Group
YR 2021
UL http://medrxiv.org/content/early/2021/07/01/2021.06.28.21259503.abstract
AB Magnetic resonance image (MRI) processing pipelines use average templates to enable standardization of individual MRIs in a common space. MNI-ICBM152 is currently used as the standard template by most MRI processing tools. However, MNI-ICBM152 represents an average of 152 healthy young adult brains and is vastly different from brains of patients with neurodegenerative diseases. In those populations, extensive atrophy might cause inevitable registration errors when using an average template of young healthy individuals for standardization. Disease-specific templates that represent the anatomical characteristics of the populations can reduce such errors and improve downstream driven estimates.We present multi-sequence average templates for Alzheimer’s Dementia (AD), Fronto-temporal Dementia (FTD), Lewy Body Dementia (LBD), Mild Cognitive Impairment (MCI), cognitively intact and impaired Parkinson’s Disease patients (PD-CIE and PD-CI, respectively), individuals with Subjective Cognitive Impairment (SCI), AD with vascular contribution (V-AD), Vascular Mild Cognitive Impairment (V-MCI), Cognitively Intact Elderly (CIE) individuals, and a human phantom. We also provide separate templates for males and females to allow better representation of the diseases in each sex group.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMD is supported by a scholarship from the Canadian Consortium on Neurodegeneration in Aging (CCNA) as well as by an Alzheimer Society Research Program (ASRP) postdoctoral award. CCNA is supported by a grant from the Canadian Institutes of Health Research with funding from several partners.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The COMPASS-ND study was approved by the Jewish General Hospital Research Ethics Board. Written informed consent was obtained from all participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe average template files for all groups and sequences are available in both compressed MINC and NIfTI formats at G-Node (https://gin.g-node.org/mahsadadar/CDIP_Templates) as well as Zenodo (https://zenodo.org/record/5018356#.YNPNkExE3b0).AbbreviationsADAlzheimer’s DementiaCIECognitively Intact ElderlyFLAIRFLuid Attenuated Inversion RecoveryFTDFronto-temporal DementiaLBDLewy Body DementiaMCIMild Cognitive ImpairmentMRIMagnetic Resonance ImagingPDParkinson’s DiseasePDProton DensitySCISubjective Cognitive ImpairmentT1wT1-weightedT2wT2-weightedTEecho timeTIinversion timeTRrepetition timeV-ADVascular Alzheimer’s DementiaV-MCIVascular Mild Cognitive ImpairmentWMHWhite Matter Hyperintensity